Dianthus Therapeutics, Inc./$DNTH
1D1W1MYTD1Y5YMAX
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
- Ticker
- $DNTH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 92
- Headquarters
- New York, United States
- Website
- dianthustx.com
DNTH Metrics
BasicAdvanced
$6.4B
-
-$4.11
0.08
-
Price and volume
Market cap
$6.4B
Beta
0.08
52-week high
$116.89
52-week low
$20.31
Average daily volume
868K
Financial strength
Current ratio
26.1
Quick ratio
25.791
Long term debt to equity
0.078
Total debt to equity
0.11
Profitability
EBITDA (TTM)
-217.721
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-10,096.95%
Operating margin (TTM)
-11,441.39%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-17.69%
Return on equity (TTM)
-26.07%
Valuation
Price to revenue (TTM)
2,819.688
Price to book
5.37
Price to tangible book (TTM)
5.37
Price to free cash flow (TTM)
-34.479
Free cash flow yield (TTM)
-2.90%
Free cash flow per share (TTM)
-3.331
Growth
Revenue change (TTM)
-60.77%
Earnings per share change (TTM)
26.59%
3-year revenue growth (CAGR)
-20.53%
3-year earnings per share growth (CAGR)
-22.98%
DNTH News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.